JAK Inhibitors Beyond Arthritis: Expanding Indications and Mechanisms of JAK Inhibitors in Rheumatology
- 1Clinical Center of Montenegro, Clinic of Internal Medicine, 81000 Podgorica, Montenegro
- 2Faculty of Medicine, Institute of Rheumatology, University of Belgrade, 11000 Belgrade, Serbia
- 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Inflammation, Fibrosis and Ageing Initiative (INFLAGE), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, 20132 Milan, Italy
Abstract
Clinical development of conventional JAK, selective TYK2, and dual TYK2/JAK1 inhibitors has expanded beyond inflammatory arthritis, but evidence across systemic rheumatic diseases varies substantially and the agents are not pharmacologically interchangeable. We conducted a structured narrative review of PubMed/MEDLINE and ClinicalTrials.gov with an initial search in May 2026 and targeted updates through 9 November 2026, prioritizing randomized trials and interpreting observational studies and case reports as exploratory. Findings were organized by the highest direct clinical evidence and the practical conclusions that evidence can support. Upadacitinib for giant cell arteritis and brepocitinib for adult dermatomyositis now have phase 3 evidence and regulatory approval in the United States; upadacitinib is also approved for giant cell arteritis in the European Union. In the 52-week VALOR trial, brepocitinib 30 mg improved mean Total Improvement Score versus placebo (46.5 vs. 31.2; p < 0.001), while serious infections were more frequent (10% vs. 1%). Evidence in systemic lupus erythematosus remains mixed, and phase 3 programs are ongoing. A randomized baricitinib trial in Sjögren disease has a promising conference-abstract result, but full peer-reviewed data are not yet available. Evidence in polymyalgia rheumatica, systemic sclerosis, other vasculitides, VEXAS, and monogenic inflammatory diseases remains less mature. Clinical use should follow disease-specific evidence, regulatory status, and individualized safety assessment; pathway plausibility alone does not establish efficacy or predict response.
Related
- Factor XI and XIa Inhibitors: A State-of-the-Art Review Across Clinical Indications.
- Medicare Part D formulary coverage of SGLT2 inhibitors across cardiovascular-kidney-metabolic indications, 2019-2026.
- PATIENT-REPORTED OUTCOMES FOLLOWING DISCONTINUATION OF TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS REMISSION/LOW DISEASE ACTIVITY: A RANDOMIZED PLACEBO-CONTROLLED TRIAL
- Preventive Effectiveness of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors
- Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects
BibTeX
@article{bogojevic2026inhibitors,
title = {{JAK Inhibitors Beyond Arthritis: Expanding Indications and Mechanisms of JAK Inhibitors in Rheumatology}},
author = {Milan Bogojevic and Natasa Miketic and Elvira Strujic and Dragana Pravilovic Lutovac and Slavica Pavlov Dolijanovic and Lorenzo Dagna and Marco Matucci-Cerinic and Rifat Medjedovic and Milica Markovic},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15228894},
url = {https://www.mdpi.com/2077-0383/15/22/8894},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - JAK Inhibitors Beyond Arthritis: Expanding Indications and Mechanisms of JAK Inhibitors in Rheumatology
AU - Milan Bogojevic
AU - Natasa Miketic
AU - Elvira Strujic
AU - Dragana Pravilovic Lutovac
AU - Slavica Pavlov Dolijanovic
AU - Lorenzo Dagna
AU - Marco Matucci-Cerinic
AU - Rifat Medjedovic
AU - Milica Markovic
PY - 2026
DA - 2026/11/13
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15228894
UR - https://www.mdpi.com/2077-0383/15/22/8894
AB - Clinical development of conventional JAK, selective TYK2, and dual TYK2/JAK1 inhibitors has expanded beyond inflammatory arthritis, but evidence across systemic rheumatic diseases varies substantially and the agents are not pharmacologically interchangeable. We conducted a structured narrative review of PubMed/MEDLINE and ClinicalTrials.gov with an initial search in May 2026 and targeted updates through 9 November 2026, prioritizing randomized trials and interpreting observational studies and case reports as exploratory. Findings were organized by the highest direct clinical evidence and the practical conclusions that evidence can support. Upadacitinib for giant cell arteritis and brepocitinib for adult dermatomyositis now have phase 3 evidence and regulatory approval in the United States; upadacitinib is also approved for giant cell arteritis in the European Union. In the 52-week VALOR trial, brepocitinib 30 mg improved mean Total Improvement Score versus placebo (46.5 vs. 31.2; p < 0.001), while serious infections were more frequent (10% vs. 1%). Evidence in systemic lupus erythematosus remains mixed, and phase 3 programs are ongoing. A randomized baricitinib trial in Sjögren disease has a promising conference-abstract result, but full peer-reviewed data are not yet available. Evidence in polymyalgia rheumatica, systemic sclerosis, other vasculitides, VEXAS, and monogenic inflammatory diseases remains less mature. Clinical use should follow disease-specific evidence, regulatory status, and individualized safety assessment; pathway plausibility alone does not establish efficacy or predict response.
SN - 2077-0383
ER -